Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
  • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
  • A61F13/47—Sanitary towels, incontinence pads or napkins
  • A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
  • A61F13/47218—Sanitary towels, incontinence pads or napkins specially adapted for female use with a raised crotch region, e.g. hump
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
  • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
  • A61F13/47—Sanitary towels, incontinence pads or napkins
  • A61F13/475—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means
  • A61F13/4751—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction
  • A61F13/4756—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction the means consisting of grooves, e.g. channels, depressions or embossments, resulting in a heterogeneous surface level
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
  • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
  • A61F13/47—Sanitary towels, incontinence pads or napkins
  • A61F13/476—Sanitary towels, incontinence pads or napkins characterised by encircling the crotch region of the undergarment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
  • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
  • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
  • A61F13/51113—Topsheet, i.e. the permeable cover or layer facing the skin comprising an additive, e.g. lotion or odour control

Definitions

• the present disclosure relates to an absorbent article.
• Disposable absorbent articles are known to have lotion coated onto a liquid-permeable top sheet in a pattern shape, comprising a plurality of strips separated by a plurality of regions without lotion (for example, PTL 1) .
• a pattern shape comprising a plurality of strips separated by a plurality of regions without lotion (for example, PTL 1) .
• the effect of- the lotion can lower the adhesive force of the hot-melt adhesive (H A) bonding the top sheet to the back sheet, and can reduce the strength of the absorbent article.
• H A hot-melt adhesive
• the disclosure provides an absorbent article having a lengthwise direction and a widthwise direction.
• the absorbent article comprises a liquid-permeable top sheet provided on the skin facing side, a liquid-impermeable back sheet provided on the non-skin facing side, and a liquid-retaining absorbent body situated between the top sheet and the back sheet.
• the top sheet has a blood modifying agent-coated region on which a blood modifying agent is coated.
• the blood modifying agent has an IOB of 0.00-0.60, a melting point of no higher than 45°C and a water solubility of no greater than 0.05 g in 100 g of water at 25°C.
• the blood modifying agent-coated region does not reach to the edges of the absorbent article.
• Fig. 1 is a partial cutaway plan view showing an absorbent article according to a first embodiment of the invention .
• Fig. 2 is a schematic cross-sectional view showing a cross-section of the absorbent article of Fig. 1 along line A-A.
• Fig. 3 is a plan view showing an absorbent article according to a second embodiment of the invention.
• Fig. 4 is a plan view showing an absorbent article according to a third embodiment of the invention.
• Fig. 5 is a schematic cross-sectional view showing a cross-section of the absorbent article of Fig. 4 along line C-C.
• Fig. 6 is a plan view showing an absorbent article according to a fourth embodiment of the invention.
• Fig. 7 is a plan view showing an absorbent article according to a fifth embodiment of the invention.
• Fig. 8 is a plan view showing an absorbent article according to a sixth embodiment of the invention.
• Fig. 9 is an electron micrograph of the skin contact surface of a top sheet in a sanitary napkin wherein the top sheet comprises tri-C2L oil fatty acid glycerides.
• Fig. 10 is a pair of photomicrographs of menstrual blood containing and not containing a blood modifying agent.
• Fig. 11 is a diagram illustrating a method of measuring surface tension. DESCRIPTION OF EMBODIMENTS
• Fig. 1 is partial cutaway plan view showing an absorbent article according to a first embodiment of the invention
• Fig. 2 is a schematic cross-sectional view showing a cross-section of the absorbent article of Fig. 1 along line A-A
• the absorbent article 1A comprises a liquid-permeable top sheet 2 provided on the skin facing side, a liquid-impermeable back sheet 3 provided on the non-skin facing side, a liquid-retaining absorbent body 4 situated between the top sheet 2 and the back sheet 3, and, in this particular embodiment, a pair of side sheets 5 provided on both sides of the top sheet 2 in the widthwise direction.
• the absorbent article 1A has a body section 6 and, in this particular embodiment, a pair of wing sections 7 extending from the body section 6 in the widthwise direction.
• the top sheet 2 has a blood
• top sheet 2 and back sheet 3 are bonded at a seal section 9, for example by embossing.
• back sheet 3 and side sheet 5 are also bonded
• seal sections 9,10 are provided on the outer
• attachment parts 11,12 are provided on the non-skin facing side of the back sheet 3.
• the widthwise direction of the absorbent article 1A is the X- axial direction
• the lengthwise direction is the Y- axial direction
• the planar direction is the direction of the plane defined by the X-axial and Y-axial
• the shape of the body section 6 is not particularly restricted so long as it is a shape suited to the female body and the shape of shorts, such as roughly
• the dimensions of extension in the lengthwise direction of the outer shape of the body section 6 are preferably 100-500 mm and more preferably 150-350 mm. Also, the dimensions of extension in the widthwise direction of the outer shape of the body section 6 are preferably 30-200 mm and more preferably 40-180 mm.
• the top sheet 2 passes menstrual blood that has been excreted from the wearer into the absorbent body 4 provided under it.
• the top sheet 2 holds the absorbent body 4 in a manner with the absorbent body 4 held between it and the back sheet 3. All or a portion of the top sheet 2 is liquid-permeable, and the liquid-permeable areas of the top sheet 2 may be formed, for example, of a liquid-permeable nonwoven fabric or woven fabric, a resin film with a plurality of liquid-permeable holes formed therein, or a net-like sheet with a plurality of mesh holes.
• the material used for the nonwoven fabric or woven fabric in the top sheet 2 may be either natural fibers or chemical fibers.
• natural fibers include cellulose such as ground pulp and cotton.
• chemical fibers include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic
• thermoplastic hydrophobic chemical fibers include monofilaments of polyethylene (PE) , polypropylene (PP) and polyethylene terephthalate
• PET PET
• fibers obtained by graft polymerization of PE and PP fibers obtained by graft polymerization of PE and PP, and composite fibers with a core-sheath structure or the like.
• Fabrication of a nonwoven fabric to be used in the top sheet 2 may be accomplished for example by web forming, with either a dry method (carding method, spunbond method, meltblown method or airlaid method) or wet method, or with a combination of a dry method and a wet method.
• the web bonding method for fabrication of a nonwoven fabric to be used in the top sheet 2 may be thermal bonding, needle punching, chemical bonding or the like, with no particular restriction to these methods.
• Spunlace formed into a sheet by a hydroentangling method may also be used in the top sheet 2.
• irregularities on the skin facing side such as a
• nonwoven fabric having heat-shrinkable fibers or the like for shrinking on the lower layer side to form
• irregularities on the upper layer side or a nonwoven fabric in which irregularities are formed by applying air during web formation. Forming irregularities on the skin facing side in this manner can reduce the contact area between the top sheet 2 and the skin.
• fibers in the nonwoven fabric for the top sheet 2 there may be used, for example, core-sheath type fibers wherein the melting point of the core component is higher than that of the sheath component, eccentric core-sheath type fibers, or side-by-side type composite fibers wherein the melting points of the left and right
• hollow type fibers or flat fibers, or shaped fibers such as Y-shaped fibers or C-shaped fibers, solid crimped fibers such as latent crimped or developed crimped fibers, or split fibers that have been split by a physical load such as a water stream, heat or embossing, may be combined in a nonwoven fabric to be used for the top sheet 2.
• the size of the fibers of a nonwoven fabric for use in the top sheet 2 is preferably 1.1-8.8 dtex.
• hydrophobic synthetic fibers are used in the top sheet 2, in consideration of uptake of fluids and rewet backing by the top sheet 2, the hydrophobic
• synthetic fibers may be mixed with a hydrophilic agent, water-repellent agent or the like, or the hydrophobic synthetic fibers may be coated with a hydrophilic agent, water-repellent agent or the like.
• the hydrophobic synthetic fibers may also be imparted with hydrophilicity by corona treatment or plasma treatment. This will allow the hydrophilic areas and lipophilic areas to be mutually isolated in the blood modifying agent-coated region 8A when the blood modifying agent is lipophilic, and both the hydrophilic components (mainly plasma) and lipophilic components (mainly blood cells) in menstrual blood will rapidly migrate from the top sheet 2 into the absorbent body 4.
• an inorganic filler such as titanium oxide, barium sulfate or calcium carbonate may be added to the fibers of the nonwoven fabric used in the top sheet 2.
• the inorganic filler may be added only to the core or only to the sheath.
• the resin film or net-like sheet can be formed from polypropylene (PP) , polyethylene (PE), polyethylene terephthalate (PET), or the like.
• the top sheet 2 has a blood modifying agent-coated region 8A coated with a blood modifying agent.
• the blood modifying agent will now be described in detail.
• the blood modifying agent-coated region 8A does not reach to the edges of the absorbent article 1A. This can limit weakening of the bonding at the edge sections of the absorbent article caused by the blood modifying agent, and can inhibit reduction in strength of the absorbent article 1A. It can also minimize the coating amount of the blood modifying agent and thus reduce production cost for the absorbent article 1A.
• the blood modifying agent-coated region 8A is preferably within the absorbent body region (4) .
• the absorbent body region (4) is the region of the top sheet 2 at which the absorbent body 4 is present on the non-skin facing side of the top sheet 2.
• the blood modifying agent lowers the viscosity and surface tension of menstrual blood and allows rapid migration of menstrual blood from the top sheet 2 to the absorbent body 4, and therefore menstrual blood that has been excreted by the wearer does not easily spread from the blood modifying agent-coated region 8A outward in the planar direction. It is therefore possible to inhibit menstrual blood that has been excreted by the wearer into the top sheet 2 from spreading to the outside of the absorbent body region (4). It can also further minimize the coating amount of the blood modifying agent and thus reduce production cost for the absorbent article 1A.
• the blood modifying agent-coated region 8A also preferably does not reach the seal sections 9,10 present on the outer periphery of the absorbent article 1A. This can limit weakening of the bonding at the seal sections 9,10 caused by the blood modifying agent, and can inhibit reduction in strength of the absorbent article 1A and decomposition of the absorbent article 1A. It can also minimize the coating amount of the blood modifying agent and thus reduce production cost for the absorbent article 1A.
• the blood modifying agent-coated region 8A more preferably does not reach to the region 12 where the top sheet 2 and side sheets 5 overlap (see Fig. 2). This can limit weakening of bonding between the top sheet 2 and side sheet 5 caused by the blood modifying agent, and can inhibit reduction in strength of the absorbent article 1A and decomposition of the absorbent article 1A.
• the length of the blood modifying agent-coated region 8A in the lengthwise direction is preferably 50 mm or greater and even more preferably 100 mm or greater.
• the length of the blood modifying agent-coated region 8A in the widthwise direction is preferably 10 mm or greater and even more preferably 30 mm or greater.
• the coating basis weight of the blood modifying agent on the top sheet 2 is preferably 1-30 g/m 2 and more preferably 3-10 g/m 2 . If the coating basis weight of the blood modifying agent is smaller than 1 g/m 2 , it may be difficult to coat the blood modifying agent on the top sheet 2 in a stable manner, and if the coating basis weight of the blood modifying agent is greater than 30 g/m , the top sheet 2 may become greasy.
• the blood modifying agent After the blood modifying agent has been heated to a prescribed temperature, it is coated onto the top sheet 2 using a contact coater such as a slot coater, or a non- contact coater such as a spray coater, curtain coater or spiral coater. From the viewpoint of allowing uniform dispersion of the blood modifying agent in droplet form in the blood modifying agent-coated region 8A, and avoiding damage to the top sheet 2, it is preferred to coat the blood modifying agent on the top sheet 2 using a non-contact coater.
• a contact coater such as a slot coater, or a non- contact coater such as a spray coater, curtain coater or spiral coater.
• the nonwoven fabric may also be coated with a blood modifying agent.
• the top sheet 2 may also be coated with the blood modifying agent in the step of producing the absorbent article 1A.
• the blood modifying agent is preferably coated on the top sheet 2 in the step of producing the absorbent article 1A, since this can minimize equipment investment.
• the top sheet 2 may be coated with the blood modifying agent just before the step of wrapping the - absorbent article 1A.
• the back sheet 3 prevents menstrual blood that has been absorbed into the absorbent body 4 from leaking to the outside.
• a liquid-impermeable film mainly comprises polyethylene (PE) and polypropylene (PP) , an air-permeable resin film, a composite film comprising an air-permeable resin film bonded to a spunbond or spunlace nonwoven fabric, or an SMS ( spunbond-meltblown-spunbond) nonwoven fabric
• a resin film with a basis weight of 15-30 g/m 2 composed mainly of a low- density polyethylene (LDPE) resin, for example, as the back sheet 3.
• LDPE low- density polyethylene
• the absorbent body 4 has the function of absorbing and retaining menstrual blood.
• the absorbent body 4 preferably has high bulk, is resistant to deformation and has low chemical irritation.
• the absorbent body 4 used may be, for example, an absorbent body comprising
• SAP absorbent polymer
• hydrophilic fibers or an absorbent polymer covered with a covering material include cellulose such as ground pulp and cotton, regenerated cellulose such as rayon or fibril rayon, semi-synthetic cellulose such as acetate and triacetate, particulate polymers, filamentous polymers, thermoplastic hydrophobic chemical fibers, hydrophilicized thermoplastic hydrophobic chemical fibers, and mixtures of the foregoing materials.
• Cellulose foam and synthetic resin continuous foam may also be used in the absorbent body 4. Also, a foam or sheeted material may be pulverized and then molded into the absorbent body shape for use as the absorbent body 4.
• ground pulp is used as the hydrophilic fibers for the absorbent body 4, in consideration of reducing cost and facilitating molding.
• particulate polymers such as sodium acrylate copolymer which exhibits absorptivity and hygroscopicity .
• silver, copper, zinc, silica, active carbon, an aluminosilicate compound, zeolite or the like may also be added to the polymer. This can impart functions such as deodorant, antibacterial or heat- absorbing effects to the polymer.
• the covering material of the absorbent body 4 which comprises hydrophilic fibers or an absorbent polymer covered with a covering material is not particularly restricted so long as it has liquid-permeability and a barrier property so that the polymer absorbent body does not slip.
• a woven fabric or nonwoven fabric may be used as the covering material.
• the material of the woven fabric or nonwoven fabric may be either natural fibers or chemical fibers. Natural fibers include cellulose such as ground pulp and cotton. Chemical fibers include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fibers, and hydrophilicized thermoplastic hydrophobic chemical fibers.
• Web forming for fabrication of a nonwoven fabric to be used in a covering material may be accomplished by either a dry method (carding method, spunbond method, meltblown method or airlaid method) or wet method, or a combination of a dry method and a wet method.
• the method of bonding the nonwoven fabric to be used in a covering material may be thermal bonding, needle punching, chemical bonding or the like, with no particular
• the covering material is preferably tissue composed mainly of ground pulp and formed by a wet method, in consideration of reducing cost and increasing the barrier property.
• the absorbent body may be embossed for deformation and twisting of the absorbent body 4 during use, and also for thickness adjustment. Embossing of the absorbent body 4 is accomplished, for example, by passing the absorbent body between a patterned embossing roll and a flat roll.
• the embossing roll pattern may be selected from among lattice-like, dot-like and wavy patterns, but is preferably a lattice-like pattern for easier
• Embossing of the absorbent body 4 can guide diffusion of menstrual blood in the
• absorbent sheet and polymer sheet may be used in the absorbent body 4. This can result in a thinner absorbent body 4.
• the thickness of the absorbent body 4 is preferably 0.3-5 mm.
• Absorbent sheets include pulp sheets prepared as sheets from fibers using a binder or the like.
• Polymer sheets include composite sheets obtained by forming sheets of ground pulp or fiber mixed with a particulate polymer.
• a sheet formed by mixing a particulate polymer with fibers may be a sheet of a particulate polymer dispersed in a laminar form in the fibers, or a sheet in which the particulate polymer is dispersed in the fibers in a three-dimensional manner.
• the fibers to be used in an absorbent sheet or polymer sheet are preferably cellulose fibers such as wood pulp, regenerated cellulose fibers such as rayon or cupra, hydrophilic synthetic fibers such as polyvinyl alcohol fibers or polyacrylonitrile fibers, or fibers of polyethylene, polypropylene, polyethylene terephthalate, polyethylene/polypropylene composite fibers or
• polyethylene/polyethylene terephthalate composite fibers where the fibers surfaces have been hydrophilicized with a surfactant or the like. From the viewpoint of
• the fibers to be used in an absorbent sheet or polymer sheet are preferably cellulose fibers.
• a particulate polymer to be used in a polymer sheet is preferably a polymer that can absorb and retain over 20 times its own weight in fluid, and that can gel.
• Such polymers include starch, crosslinked carboxymethylated cellulose,
• the side sheet 5 prevents menstrual blood from leaking through the top sheet 2 to the outside of the absorbent article 1 in the widthwise direction.
• the side sheet 5 preferably has hydrophobicity and water- repellency.
• a spunbond nonwoven fabric or SMS nonwoven fabric, for example, is used for the side sheet 5.
• an air-through nonwoven fabric that can reduce rubbing irritation on the skin is preferably used as the side sheet 5.
• the side sheet is not essential to the absorbent article, and the absorbent article does not need to be provided with a side sheet.
• the top sheet 2, back sheet 3, absorbent body 4 and side sheet 5 are preferably bonded together to prevent interlayer separation between them. Their bonding may be accomplished, for example, by embossing, ultrasonic waves, with an adhesive such as a hot-melt adhesive, or by a combination of the foregoing techniques.
• the top sheet 2 and back sheet 3 are bonded at a seal section 9 by embossing.
• the back sheet 3 and side sheet 5 are also bonded at a seal section 10 by embossing.
• the top sheet 2 and side sheet 5 are bonded by a hot-melt adhesive on both sides of the body section 6.
• the top sheet 2 and back sheet 3 may also be bonded at the seal section 9 with an adhesive.
• the top sheet and back sheet, or the top sheet and back sheet and side sheet may be passed together between a patterned embossing roll and a flat roll, and the perimeter of the absorbent body embossed (a method known as round sealing) .
• This will form seal sections 9,10 in the absorbent article 1A.
• Emboss patterns include lattice-like patterns, zigzag patterns and wavy patterns.
• the emboss pattern is preferably intermittently elongated.
• a hot-melt adhesive is used to bond the top sheet, back sheet, absorbent body and side sheet
• a hot- melt adhesive is coated onto each sheet by a coating method such as spiral coating, coater coating, curtain coater coating or Summit gun coating.
• the sheets are then stacked and bonded together. After the sheets have been bonded together, they may be subjected to embossing to increase the peel strength between the sheets.
• Hot-melt adhesives to be used for bonding the sheets together include pressure-sensitive adhesives and heat- sensitive adhesives composed mainly of rubber-based compounds such as styrene-ethylene-butadiene-styrene (SEBS) , styrene-butadiene-styrene (SBS) or styrene- isoprene-styrene (SIS) , or composed mainly of olefin- based compounds such as linear low-density polyethylene, and water-sensitive adhesives such as polyvinyl alcohol, carboxylmethylcellulose and gelatin comprising water- soluble polymers or polyvinyl acetate and sodium
• the hot-melt adhesive is preferably used as the hot-melt adhesive for bonding between the sheets.
• Specific examples include adhesives prepared by melt mixing of 5-25% of SEBS, 40-60% of an alicyclic saturated hydrocarbon, 1-10% of an aromatic-modified terpene and 15-35% of an additive.
• the wing sections 7 if provided in the absorbent article 1A stably anchor the absorbent article 1A to underwear. After the wing sections 7 have been folded on the outer side of the underwear, the absorbent article is attached to the crotch section of the underwear through the attachment part 12 to allow the absorbent article 1A to be stably anchored to the underwear.
• the shapes of the wing sections 7 are roughly rectangular.
• the attachment part 11 on the non-skin facing side of the back sheet 3 anchors the body section 6 to the inside of the crotch section of the underwear
• the attachment part 12 on the non-skin facing side of the wing sections 7 anchors the wing sections 7 to the outside of the crotch section of the underwear.
• the pressure-sensitive adhesive used to form the attachment parts 11,12 is preferably, for example, one composed mainly of a styrene-based polymer, tackifier or
• Styrene-based polymers include styrene-ethylene-butylene-styrene block copolymer, styrene- butylene polymer, styrene-butylene-styrene block
• styrene-isobutylene-styrene copolymer any of which may be used alone or as polymer blends of 2 or more.
• Styrene-ethylene-butylene-styrene block copolymer is preferred as the pressure-sensitive adhesive for the attachment parts 10,11 from the viewpoint of satisfactory thermostability.
• An organic compound that is solid at ordinary temperature is preferably used as the tackifier and plasticizer.
• a tackifier may be, for example, a C5 petroleum resin, C9 petroleum resin, dicyclopentadiene- based petroleum resin, rosin-based petroleum resin, polyterpene resin, terpenephenol resin or the like
• a plasticizer may be, for example, a monomer plasticizer such as tricresyl phosphate, dibutyl phthalate or dioctyl phthalate, or a polymer plasticizer such as a vinyl polymer or polyester.
• the blood modifying agent to be coated onto the top sheet 2 will now be explained in detail.
• the blood modifying agent can lower the viscosity and surface tension of menstrual blood after absorption of highly viscous menstrual blood by the top sheet 2, allowing menstrual blood to migrate rapidly from the top sheet 2 to the absorbent body 4, and therefore highly viscous menstrual blood does not easily remain on the top sheet 2, and the top sheet 2 has a smooth feel without
• the blood modifying agent of this disclosure has an
• IOB of about 0.00 to about 0.60, a melting point of no higher than about 45°C, and a water solubility of no greater than about 0.05 g in lOOg of water at 25°C.
• the IOB is an indicator of the hydrophilic-lipophilic balance, and as used herein, it is the value calculated by the following formula by Oda et al.:
• IOB inorganic value/organic value.
• the inorganic value and the organic value are based on the organic paradigm described in "Organic compound predictions and organic paradigms" by Fujita A., Kagaku no Ryoiki (Journal of Japanese Chemistry), Vol.11, No.10 (1957) p.719-725.
• the IOB is about 0.00-
• melting point refers to the peak top temperature for the endothermic peak during conversion from solid to liquid, upon measurement with a differential scanning calorimetry analyzer at a
• the melting point may be measured using a Model DSC-60 DSC measuring apparatus by Shimadzu Corp., for example.
• the blood modifying agent has a melting point of no higher than about 45°C, it may be either liquid or solid at room temperature, or in other words, the melting point may be either about 25°C or higher or below about 25°C, and for example, it may have a melting point of about -5°C or about -20°C.
• the reason for a melting point of no higher than about 45°C for the blood modifying agent will be explained below.
• the blood modifying agent does not have a lower limit for the melting point, but the vapor pressure is preferably low.
• modifying agent is preferably about 0.00-0.01 Pa, more preferably about 0.000-0.001 Pa and even more preferably about 0.0000-0.0001 Pa, at 1 atmosphere, 25°C.
• the vapor pressure is preferably about 0.00-0.01 Pa, more
• vapor pressure is high, gasification may occur during storage and the amount of blood modifying agent may be reduced, and may create problems such as odor during wear .
• the melting point of the blood modifying agent may also differ depending on the weather or duration of wear. For example, in regions with a mean atmospheric
• using a blood modifying agent with a melting point of no higher than about 10°C may allow the blood modifying agent to stably modify blood after excretion of menstrual blood, even if it has been cooled by the ambient temperature.
• the melting point of the blood modifying agent is preferably at the high end of the range of no higher than about 45°C. This is because the blood modifying agent is not easily affected by sweat or friction during wearing, and will not easily migrate even during prolonged wearing.
• the water solubility of 0.00-0.05 g may be measured by adding 0.05 g of sample to 100 g of deionized water at 25°C, allowing it to stand for 24 hours, and after 24 hours, gently stirring if necessary, and then visually evaluating whether or not the sample has dissolved.
• solubility in regard to water solubility includes cases where the sample
• top sheet surfaces are coated with surfactants in order to alter the surface tension of blood and promote the rapid absorption of blood, because
• surfactants generally have high water solubility, the surfactant-coated top sheet is highly miscible with hydrophilic components (such as blood plasma) in the blood and therefore, instead, they tend to cause residue of blood on the top sheet.
• the aforementioned blood modifying agent has low water solubility and therefore, it does not cause residue of blood on the top sheet and allows rapid migration into the absorbent body.
• water solubility As used herein, a water solubility of water at 25°C may be simply referred to as "water solubility".
• weight-average molecular weight includes the concept of a polydisperse compound (for example, a compound produced by stepwise polymerization, an ester formed from a plurality of fatty acids and a plurality of aliphatic monohydric alcohols) , and a simple compound (for example, an ester formed from one fatty acid and one aliphatic monohydric alcohol) , and in a system comprising i molecules with molecular weight Mi (i
• the weight-average molecular weights are the values measured by gel permeation chromatography (GPC), based on polystyrene.
• the GPC measuring conditions may be the following, for example.
• weight-average molecular weights listed in the examples of the present specification were measured under the conditions described below.
• the blood modifying agents is selected from the group consisting of the following items (i)- (iii) , and any combination thereof:
• hydrocarbon moiety and (iii-3) one or more groups each selected from the group consisting of carboxyl group (- COOH) and hydroxyl group (-OH) substituting a hydrogen of the hydrocarbon moiety.
• hydrocarbon refers to a compound composed of carbon and hydrogen, and it may be a chain hydrocarbon, such as a paraffinic hydrocarbon (containing no double bond or triple bond, also referred to as alkane) , an olefin-based hydrocarbon (containing one double bond, also referred to as alkene) , an acetylene- based hydrocarbon (containing one triple bond, also referred to as alkyne) , or a hydrocarbon comprising two or more bonds each selected from the group consisting of double bonds and triple bonds, and cyclic hydrocarbon, such as aromatic hydrocarbons and alicyclic hydrocarbons.
• hydrocarbons and alicyclic hydrocarbons with chain hydrocarbons being more preferred, paraffinic
• hydrocarbons olefin-based hydrocarbons and hydrocarbons with two or more double bonds (containing no triple bond) being more preferred, and paraffinic hydrocarbons being even more preferred.
• Chain hydrocarbons include linear hydrocarbons and branched hydrocarbons.
• carboxyl groups bond with metals and the like in menstrual blood, drastically increasing the inorganic value from 150 to 400 or greater, and therefore a blood modifying agent with carboxyl groups can increase the IOB value to more than about 0.6 during use, potentially lowering the affinity with blood cells.
• the blood modifying agent is a compound selected from the group consisting items (i') _ (iii') z and any combination thereof:
• hydrocarbon moiety and (ii'-2) one or more bonds each selected from the group consisting of carbonyl bond (-CO- ) , at least one ester bond (-COO-) , at least one
• hydrocarbon hydrocarbon, and (iii'-3) one or more groups each
• bonds are inserted in the compound of ( ⁇ ') or (iii'), i.e., when 2 or more bonds each selected from the group consisting of carbonyl bonds (-CO-), ester bonds (-COO-) , carbonate bonds (- OCOO-) and ether bonds (-0-) are inserted, the bonds are not adjacent to each other, and at least one carbon atom lies between each of the bonds.
• the blood modifying agent is more preferably a compound with no more than about 1.8 carbonyl bonds (-C0- ) , no more than 2 ester bonds (-C00-) , no more than about 1.5 carbonate bonds (-OCOO-) , no more than about 6 ether bonds (-0-) , no more than about 0.8 carboxyl groups (- COOH) and/or no more than about 1.2 hydroxyl groups (-
• the blood modifying agent is selected from the group consisting of the following items (A) -(F), and any combination thereof:
• the (A) ester of (Al) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety, and (A2) a compound having a chain hydrocarbon moiety and 1 carboxyl group substituting a hydrogen on the chain hydrocarbon moiety includes esters of a compound with 4, 3 or 2 hydroxyl groups and a compound with 1 carboxyl group, and it is not necessary for all of the hydroxyl groups to be esterified so long as the IOB, melting point and water solubility are within the aforementioned ranges.
• chain hydrocarbon tetraols such as alkanetetraols, including
• alkanetriols including glycerins, and chain hydrocarbon diols such as alkanediols, including glycols.
• chain hydrocarbon diols such as alkanediols, including glycols.
• (A2) a compound having a chain hydrocarbon moiety and 1 carboxyl group substituting a hydrogen on the chain hydrocarbon moiety (hereunder also referred to as
• compound (A2) include compounds in which one hydrogen on the hydrocarbon is substituted with one carboxyl group (-COOH) , such as fatty acids.
• Examples for compound (A) include (ai) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) an ester of a chain hydrocarbon triol and at least one fatty acid, and (a3) an ester of a chain hydrocarbon diol and at least one fatty acids.
• Examples of an ester of a chain hydrocarbon tetraol and at least one fatty acid include tetraesters of pentaerythritol and fatty acids, represented by the following formula (1):
• diesters of pentaerythritol and fatty acids represented by the following formula (3) :
• R 1 -R 4 each represent a chain
• pentaerythritol and fatty acids are not particularly restricted as long as the pentaerythritol and fatty acid esters satisfy the
• saturated fatty acids such as C2-C30 saturated fatty acids, including acetic acid (C 2 ) (C 2 representing the number of carbons, corresponding to the number of carbons of each of R 1 C, R 2 C, R 3 C or RC, same hereunder), propanoic acid (C 3 ) , butanoic acid (C 4 ) and isomers thereof such as 2-methylpropanoic acid (C 4 ) , pentanoic acid (C 5 ) and isomers thereof such as 2-methylbutanoic acid (C 5 ) and 2 , 2-dimethylpropanoic acid (C 5 ) , hexanoic acid (C 6 ) , heptanoic acid (C 7 ) , octanoic acid (C 8 ) and isomers thereof, such as 2-ethylhexanoic acid (C 8 ) , nonanoic acid (C 9 ) , decanoic acid
• eicosanoic acid (C20) , docosanoic acid (C 22 ) , tetracosanoic acid (C 24 ) , hexacosanoic acid (C 26 ) , octacosanoic acid (C 28 ) and triacontanoic acid (C 30 ) , as well as isomers of the foregoing (excluding those mentioned above) .
• the fatty acid may also be an unsaturated fatty acid.
• unsaturated fatty acids include C3-C20 unsaturated fatty acids, such as monounsaturated fatty acids including crotonic acid (C 4 ) , myristoleic acid (Ci 4 ) , palmitoleic acid (Ci 6 ) , oleic acid (Ci 8 ) , elaidic acid (Cis) , vaccenic acid (Cie) , gadoleic acid (C 2 o) and eicosenoic acid (C 2 o) , di-unsaturated fatty acids
• linolic acid (Cie) and eicosadienoic acid (C 2 o) tri-unsaturated fatty acids including linolenic acids, such as a-linolenic acid (Cie) and ⁇ -linolenic acid (Ci 8 ) , pinolenic acid (C i8 ) , eleostearic acids, such as a- eleostearic acid (Cie) and ⁇ -eleostearic acid (Cie) , Mead acid (C 2 o) , dihomo-y-linolenic acid (C 2 o) and
• the ester of pentaerythritol and a fatty acid is preferably an ester of pentaerythritol and a fatty acid, which is derived from a saturated fatty acid, i.e., an ester of pentaerythritol and a saturated fatty acid.
• ester of pentaerythritol and a fatty acid is preferably a diester, triester or
• tetraester more preferably a triester or tetraester, and even more preferably a tetraester.
• the IOB is 0.60 if the total number of carbons of the fatty acid composing the tetraester of the
• pentaerythritol and fatty acid i.e., the total number of carbons of the R 1 C, R 2 C, R 3 C and R 4 C portions in formula (1), is 15.
• pentaerythritol and fatty acid is approximately 15 or greater, the IOB satisfies the condition of being within about 0.00 to 0.60.
• tetraesters of pentaerythritol and fatty acids examples include tetraesters of pentaerythritol with
• hexanoic acid C 6
• heptanoic acid C 7
• octanoic acid C 8
• 2-ethylhexanoic acid ⁇ Cg nonanoic acid
• nonanoic acid Cg
• decanoic acid Ci 0
• dodecanoic acid Ci 2
• the IOB is 0.58 if the total number of carbons of the fatty acid composing the triester of the pentaerythritol and fatty acid, i.e., the total number of carbons of the
• F ⁇ C, R 2 C and R 3 C portions in formula (2) is 19.
• the IOB satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.59 if the total number of carbons of the fatty acid composing the diester of the pentaerythritol and fatty acid, i.e., the total number of carbons of the
• R 1 C or R 2 C portion in formula (3) is 22.
• the IOB satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.60 if the total number of carbons of the fatty acid composing the monoester of the pentaerythritol and fatty acid, i.e., the total number of carbons of the
• R X C portion in formula (4) is 25.
• the IOB satisfies the condition of being within about 0.00 to 0.60.
• pentaerythritol and fatty acids include UNISTAR H-408BRS and H-2408BRS-22 (mixed product) (both products of NOF Corp . ) .
• esters of a chain hydrocarbon triol and at least one fatty acid examples include triesters of glycerin and fatty acids, represented by formula (5) :
• R 5 -R 7 each represent a chain hydrocarbon.
• the fatty acid composing the ester of glycerin and a fatty acid is not particularly restricted so long as the ester of glycerin and a fatty acid satisfies the conditions for the IOB, melting point and water solubility, and for example, there may be mentioned the fatty acids mentioned for the " (ai) Ester of chain hydrocarbon tetraol and at least one fatty acids", namely saturated fatty acids and unsaturated fatty acids, and in consideration of the potential for degradation by oxidation and the like, the ester is preferably a
• glycerin and fatty acid ester which is derived from a saturated fatty acid, i.e., an ester of glycerin and a saturated fatty acid.
• the ester of glycerin and a fatty acid is preferably a diester or triester, and more preferably a triester.
• a triester of glycerin and a fatty acid is also known as a triglyceride, and examples include triesters of glycerin and octanoic acid (C 8 ) , triesters of glycerin and decanoic acid (Cio) , triesters of glycerin and
• dodecanoic acid (Ci 2 ) , triesters of glycerin and 2 or more different fatty acids, and mixtures of the foregoing.
• triesters of glycerin and 2 or more fatty acids include triesters of glycerin with octanoic acid (C 8 ) and decanoic acid (Cio) , triesters of glycerin with octanoic acid (C 8 ) , decanoic acid (Cio) and
• dodecanoic acid C 12
• triesters of glycerin with octanoic acid C 8
• decanoic acid Ci 0
• preferred triesters of glycerin and fatty acids are those with no more than about 40 as the total number of carbons of the fatty acid composing the triester of glycerin and the fatty acid, i.e., the total number of carbons of the R 5 C, R 6 C and R 7 C portions in formula (5) .
• the IOB value is 0.60 when the total number of carbons of the fatty acid composing the triester of glycerin and the fatty acid, i.e., the total number of carbons of the R 5 C, R 6 C and R 7 C portions in formula (5), is 12.
• the total number of carbons of the fatty acid comprising the triester of the glycerin and fatty acid is 12.
• the IOB satisfies the condition of being within about 0.00 to 0.60.
• Triesters of glycerin and fatty acids being
• triesters of glycerin and fatty acids include tri-coconut fatty acid glycerides,
• NA36, PANACET 800, PANACET 800B and PANACET 810S, and tri-C2L oil fatty acid glycerides and tri-CL oil fatty acid glycerides all products of NOF Corp.
• a diester of glycerin and a fatty acid is also known as a diglyceride, and examples include diesters of glycerin and decanoic acid (Cio) , diesters of glycerin and dodecanoic acid (Ci 2 ) , diesters of glycerin and
• hexadecanoic acid (Ci6) , diesters of glycerin and 2 or more different fatty acids, and mixtures of the
• the IOB is 0.58 if the total number of carbons of the fatty acid composing the diester of the glycerin and fatty acid, i.e., the total number of carbons of the R 5 C and R 6 C portions in formula (6), is 16.
• the IOB satisfies the condition of being about
• onoesters of glycerin and fatty acids are also known as monoglycerides , and examples include glycerin and icosanoic acid (C 2 o) monoester, and glycerin and docosanoic acid (C22) monoester.
• the IOB is 0.59 if the number of carbons of the fatty acid composing the monoester of the glycerin and fatty acid,
• the number of carbons of the R 5 C portion in formula (7) is 19.
• the IOB satisfies the condition of being about 0.00 to 0.60.
• Examples of an ester of a chain hydrocarbon diol and at least one fatty acids include monoesters and diesters of fatty acids with C 2 -C6 chain hydrocarbon diols, such as C2-C6 glycols, including ethylene glycol, propylene glycol, butylene glycol, pentylene glycol and hexylene glycol.
• examples of an ester of a chain hydrocarbon diol and at least one fatty acid include diesters of C2-C6 glycols and fatty acids, represented by the following formula (8) :
• k represents an integer of 2-6, and R 8 and R 9 each represent a chain hydrocarbon
• k represents an integer of 2-6, and R 8 is a chain hydrocarbon.
• the fatty acid to be esterified in an ester of a C2- C 6 glycol and a fatty acid is not particularly restricted so long as the ester of the C2-C6 glycol and fatty acid satisfies the conditions for the IOB, melting point and water solubility, and for example, there may be mentioned the fatty acids mentioned for the " (ai) Ester of a chain hydrocarbon tetraol and at least one fatty acid", namely saturated fatty acids and unsaturated fatty acids, and in consideration of the potential for degradation by oxidation and the like, it is preferably a saturated fatty acid.
• IOB is 0.60 when the total number of carbons of the R 8 C and R 9 C portions is 6.
• the IOB satisfies the condition of being about 0.00-0.60.
• IOB is 0.57 when the number of carbons of the R 8 C portion is 12.
• the IOB satisfies the condition of being about 0.00-0.60.
• the ester of the C 2 -C 6 glycol and fatty acid is preferably a C 2 -C 6 glycol and fatty acid ester, which is derived from a saturated fatty acid, i.e., an ester of a C 2 -C 6 glycol and a saturated fatty acid.
• the ester of the C 2 -C 6 glycol and fatty acid is preferably a glycol and fatty acid ester derived from a glycol with a greater number of carbons, such as an ester of a glycol and a fatty acid derived from butylene glycol, pentylene glycol or hexylene glycol .
• the ester of a C 2 -C6 glycol and fatty acid is preferably a diester.
• Examples of commercial products of esters of C 2 -C6 glycols and fatty acids include COMPOL BL and COMPOL BS (both products of NOF Corp.).
• the (B) ether of (Bl) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety and (B2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety includes ethers of a compound with 4, 3 or 2 hydroxyl groups and a compound with 1 hydroxyl group, and it is not necessary for all of the hydroxyl groups to be etherified as long as the IOB, melting point and water solubility are within the aforementioned ranges.
• compound (Bl) hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety
• compound (Bl) include those mentioned for “compound (A)” as compound (Al) , such as pentaerythritol , glycerin and glycol.
• compound (B2) hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety
• 1 hydrogen on the hydrocarbon is substituted with 1 hydroxyl group (-OH) , such as aliphatic monohydric alcohols, including saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols.
• -OH hydroxyl group
• saturated aliphatic monohydric alcohols include Ci-Caa saturated aliphatic monohydric alcohols, such as methyl alcohol (Ci) (Ci representing the number of carbon atoms, same hereunder) , ethyl alcohol (C 2 ) , propyl alcohol (C 3 ) and isomers thereof, including isopropyl alcohol (C 3 ) , butyl alcohol (C 4 ) and isomers thereof, including sec-butyl alcohol (C 4 ) and tert-butyl alcohol (C 4 ) , pentyl alcohol (C 5 ) , hexyl alcohol (C 6 ) , heptyl alcohol (C 7 ) , octyl alcohol (Cs) and isomers thereof, including 2-ethylhexyl alcohol (C 8 ) , nonyl alcohol (Cg) , decyl alcohol (Cio) , dodecyl alcohol (Ci 2 ) , tetradec
• Examples for compound (B) include (bi) an ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as monoethers, diethers,
• triethers and tetraethers preferably diethers, triethers and tetraethers, more preferably triethers and
• monohydric alcohols such as monoethers and diethers, and preferably diethers.
• Examples of an ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohols include tetraethers, triethers, diethers and monoethers of pentaerythritol and aliphatic monohydric alcohols, represented by the following formulae (10) -(13):
• R 10 -R 13 each represent a chain hydrocarbon.
• Examples of an ether of a chain hydrocarbon triol and at least one aliphatic monohydric alcohol include triethers, diethers and monoethers of glycerin and aliphatic monohydric alcohols, represented by the
• R 14- R 16 each represent a chain hydrocarbon.
• Examples of an ether of a chain hydrocarbon diol and at least one aliphatic monohydric alcohol include
• n is an integer of 2-6, and R 17 and R 18 are each a chain hydrocarbon,
• n is an integer of 2-6, and R 17 is a chain hydrocarbon.
• the IOB is 0.44 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the tetraether of pentaerythritol and the aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R 10 , R 11 , R 12 and R 13 portions in formula (10), is 4.
• the total number of carbon atoms of the aliphatic monohydric alcohol i.e., the total number of carbon atoms of the R 10 , R 11 , R 12 and R 13 portions in formula (10)
• composing a tetraether of pentaerythritol and an aliphatic monohydric alcohol is approximately 4 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.57 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the triether of pentaerythritol and the
• the IOB is 0.60 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the diether of pentaerythritol and the
• aliphatic monohydric alcohol i.e., the total number of carbon atoms of the R 10 and R 11 portions in formula (12).
• the IOB value satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.59 when the number of carbon atoms of the aliphatic monohydric alcohol
• pentaerythritol and an aliphatic monohydric alcohol is approximately 22 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.50 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the triether of glycerin and the aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R 14 , R 15 and R 16 portions in formula (14), is 3.
• the total number of. carbon atoms of the aliphatic monohydric alcohol comprising a triether of glycerin and an aliphatic monohydric alcohol is
• the IOB value satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.58 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the diether of glycerin and the aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R 14 and R 15 portions in formula (15), is 9.
• the total number of carbon atoms of the aliphatic monohydric alcohol comprising a diether of glycerin and an aliphatic monohydric alcohol is
• the IOB value satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.58 when the number of carbon atoms of the aliphatic monohydric alcohol
• aliphatic monohydric alcohol is approximately 16 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.
• the IOB is 0.33 when the total number of carbon atoms of the R 17 and R 18 portions is 2.
• the number of carbon atoms of the aliphatic monohydric alcohol represented by formula (17)
• the IOB value satisfies the condition of being within about 0.00 to 0.60.
• the IOB value satisfies the condition of being within about 0.00 to 0.60.
• Compound (B) may be produced by dehydrating
• compound (C) includes esters of a compound with 4, 3 or 2 carboxyl groups and a compound with 1 hydroxyl group, and it is not necessary for all of the carboxyl groups to be esterified so long as the IOB, melting point and water solubility are within the aforementioned ranges.
• Examples of (CI) a carboxylic acid, hydroxy acid, alkoxy acid or oxoacid comprising a chain hydrocarbon moiety and 2-4 carboxyl groups substituting hydrogens on the chain hydrocarbon moiety include chain hydrocarbons
• hydrocarbon carboxylic acids with 2-4 carboxyl groups such as chain hydrocarbon dicarboxylic acids including alkanedicarboxylic acids such as ethanedioic acid, propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acids, including alkanetricarboxylic acids such as propanetrioic acid, butanetrioic acid,
• decanetrioic acid and chain hydrocarbon tetracarboxylic acids, including alkanetetracarboxylic acids such as butanetetraoic acid, pentanetetraoic acid, hexanetetraoic acid, heptanetetraoic acid, octanetetraoic acid,
• nonanetetraoic acid and decanetetraoic acid are nonanetetraoic acid and decanetetraoic acid.
• Compound (CI) includes chain hydrocarbon hydroxy acids with 2-4 carboxyl groups, including alkoxy acids with 2-4 carboxyl groups such as malic acid, tartaric acid, citric acid and isocitric acid, including chain hydrocarbon alkoxy acids with 2-4 carboxyl groups, such as O-acetylcitric acid, and chain hydrocarbon oxoacids with 2-4 carboxyl groups.
• C2 Compound having a chain hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety include those mentioned for the
• compound (B) such as aliphatic monohydric alcohols.
• Compound (C) may be (ci) an ester, for example a monoester, diester, triester or tetraester, preferably a diester, triester or tetraester, more preferably a triester or tetraester and even more preferably a
• tetraester of a chain hydrocarbon tetracarboxylic acid, hydroxy acid, alkoxy acid or oxoacid with 4 carboxyl groups, and at least one aliphatic monohydric alcohol, (c 2 ) an ester, for example, a monoester, diester or triester, preferably a diester or triester and more preferably a triester, of a chain hydrocarbon
• tricarboxylic acid hydroxy acid, alkoxy acid or oxoacid with 3 carboxyl groups, and at least one aliphatic monohydric alcohol
• an ester for example, a monoester or diester, and preferably a diester, of a chain hydrocarbon dicarboxylic acid, hydroxy acid, alkoxy acid or oxoacid with 2 carboxyl groups, and at least one aliphatic monohydric alcohol.
• Examples for compound (C) include dioctyl adipate and tributyl O-acetylcitrate, of which commercially available products exist.
• the (D) compound having a chain hydrocarbon moiety and one bond selected from the group consisting of an ether bond (-0-) , carbonyl bond (-CO-), ester bond (-COO- ) and carbonate bond (-OCOO-) inserted in-between a C-C single bond of the chain hydrocarbon moiety may be (di) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d 2 ) a dialkyl ketone, (ds) an ester of a fatty acid and an aliphatic monohydric alcohol, or
• aliphatic monohydric alcohols include compounds having the following formula (19):
• R 19 and R 20 each represent a chain
• the aliphatic monohydric alcohol composing the ether (corresponding to R 19 OH and R 20 OH in formula (19)) is not particularly restricted as long as the ether satisfies the conditions for the IOB, melting point and water solubility, and for example, it may be one of the
• the IOB is 0.50 when the total number of carbon atoms of the aliphatic monohydric alcohols composing the ether, i.e., the total number of carbons of the R 19 and R 20 portions in formula (19), is 2, and therefore when the total number of carbons of the aliphatic monohydric alcohols comprising the ether is about 2 or greater, this condition for the IOB is
• the total number of carbons of the aliphatic monohydric alcohols comprising the ether is about 6, the water solubility is as high as about 2 g, which is problematic from the viewpoint of vapor pressure as well.
• the total number of carbons of the aliphatic monohydric alcohols comprising the ether is preferably about 8 or greater.
• the dialkyl ketone may be a compound of the
• R 21 and R 22 are each an alkyl group.
• the IOB is 0.54 when the total number of carbon atoms of R 21 and R 22 is 5, and therefore this condition for the IOB is satisfied if the total number of carbons is about 5 or greater.
• the total number of carbons of dialkyl ketone is preferably about 8 or greater.
• the number of carbon atoms of dialkyl ketone is preferably about 10 or greater and more preferably about 12 or greater.
• the melting point is approximately -50°C and the vapor pressure is about 230 Pa at 20°C.
• the dialkyl ketone may be a commercially available product, or it may be obtained by a known method, such as by oxidation of a secondary alcohol with chromic acid or the like.
• esters of fatty acids and aliphatic monohydric alcohols include compounds having the
• R 23 and R 24 each represent a chain
• R 23 COOH in formula (21) include the fatty acids mentioned for the " (ai) an ester of a chain hydrocarbon tetraol and at least one fatty acids", and specifically these include saturated fatty acids and unsaturated fatty acids, with saturated fatty acids being preferred in consideration of the potential for
• the aliphatic monohydric alcohol composing the ester (corresponding to R 2 OH in formula (21) ) may be one of the aliphatic
• the IOB is 0.60 when the total number of carbon atoms of the fatty acid and aliphatic monohydric alcohol.
• the total number of carbon atoms of the R 23 C and R 24 portion in formula (21) is 5, and therefore this condition for the IOB is satisfied when the total number of carbon atoms of the R 23 C and R 24 portion is about 5 or greater.
• the vapor pressure is high at greater than 2000 Pa. In consideration of vapor pressure, therefore, the total number of carbon atoms is preferably about 12 or greater. If the total number of carbon atoms is about 11 or greater, it will be possible to satisfy the condition of a water solubility of about 0.00-0.05 g.
• esters of such fatty acids and aliphatic monohydric alcohols include esters of dodecanoic acid
• the dialkyl carbonate may be a compound of the following formula (22):
• R 25 and R 26 are each an alkyl group.
• the IOB is 0.57 when the total number of carbon atoms of R 25 and R 26 is 6, and therefore this condition for the IOB is satisfied if the total number of carbons of R 25 and R 26 is about 6 or greater .
• number of carbon atoms of R 25 and R 26 is preferably about 7 or greater and more preferably about 9 or greater.
• the dialkyl carbonate may be a commercially
• reaction between phosgene and an alcohol reaction between formic chloride and an alcohol or alcoholate, or reaction between silver carbonate and an alkyl iodide.
• the (E) polyoxy C2-6 alkylene glycol, or alkyl ester or alkyl ether thereof may be (ei) a polyoxy C 2 -6 alkylene glycol, (e 2 ) an ester of a polyoxy C 2 -e alkylene glycol and at least one fatty acid, (e3) an ether of a polyoxy C 2 -6 alkylene glycol and at least one aliphatic monohydric alcohol, (e 4 ) an ester of polyoxy C 2 -6 alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon- dicarboxylic acid, or (e 5 ) an ether of polyoxy C 2 -6 alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol .
• the polyoxy 2 - e alkylene glycol is i) a homopolymer having one backbone selected from the group consisting of polyoxy C2-C6 alkylene backbones, i.e. oxyethylene
• backbone oxypropylene backbone, oxybutylene backbone, oxypentylene backbone and oxyhexylene backbone, and having hydroxy groups at both ends
• a block copolymer having a backbone of 2 or more selected from among the aforementioned group and having hydroxy groups at both ends
• a random copolymer having a backbone of two or more selected from among the aforementioned group and having hydroxy groups at both ends.
• the polyoxy C 2 -C 6 alkylene backbone is preferably an oxypropylene backbone, oxybutylene backbone, oxypentylene backbone or oxyhexylene backbone and more preferably an oxybutylene backbone, oxypentylene backbone or
• polyoxy C2-C6 alkylene glycol is a homopolymer
• poly C 3 - 6 alkylene glycol is represented by the
• n is an integer of 3-6.
• homopolymers of formula (23) may include propylene glycol, butylene glycol, pentylene glycol or hexylene glycol homopolymer.
• n in formula (23) is about 3 to 6 and preferably about 4 to 6, and n is 2 or greater.
• n in formula (23) is a value such that the polyoxy C 2 -6 alkylene glycol has an IOB of about 0.00-
• condition for the IOB is satisfied when n is equal to or greater than about 12.
• the weight-average molecular weight of the polyoxy C2-6 alkylene glycol is preferably between about 200 and about 10,000, more preferably between about 250 and about 8,000, and even more preferably in the range of about 250 to about 5,000.
• the weight-average molecular weight of a poly C3 alkylene glycol is preferably between about 1,000 and about 10,000, more preferably between about 3,000 and about 8,000, and even more preferably between about 4,000 and about 5,000.
• weight-average molecular weight is less than about 1,000, the condition for the water solubility will not be satisfied, and a larger weight- average molecular weight will particularly tend to increase the migration rate into the absorbent body and the whiteness of the top sheet.
• alkylene glycols include UNIOLTM D-1000, D1200, D-2000, D- 3000, D-4000, PB-500 and PB-700 (both products of NOF Corp . ) .
• Esters of such polyoxy C 2 -6 alkylene glycols and at least one fatty acid include the polyoxy C 2 -6 alkylene glycols mentioned for " (ei) Polyoxy C2-6 alkylene glycol” in which one or both OH ends have been esterified with fatty acids, i.e., monoesters and diesters.
• fatty acids to be esterified in the ester of a polyoxy C2-6 alkylene glycol and at least one fatty acid include the fatty acids mentioned for the " (ai) Esters of chain hydrocarbon tetraols and at least one fatty acid", and specifically these include saturated fatty acids and unsaturated fatty acids, with saturated fatty acids being preferred in consideration of the potential for degradation by oxidation and the like.
• An example of a commercially available ester of a polyoxy C 2 -6 alkylene glycol and a fatty acid is WILLBRITE cp9 (product of NOF Corp.).
• Ethers of such polyoxy C 2 -6 alkylene glycols and at least one aliphatic monohydric alcohol include the polyoxy C 2 -6 alkylene glycols mentioned for " (ei) polyoxy
• C 2 -6 alkylene glycol wherein one or both OH ends have been etherified by an aliphatic monohydric alcohol, i.e., monoethers and diethers.
• the aliphatic monohydric alcohol to be etherified may be an aliphatic monohydric alcohol among those mentioned for "compound (B)".
• the polyoxy C2-6 alkylene glycol to be esterified for the aforementioned ester of a polyoxy C 2 -6 alkylene glycol and a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid may be any of the polyoxy C 2 -e alkylene glycols mentioned above under " (ei) Polyoxy C 2 _ 6 alkylene glycol".
• the chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid to be esterified may be any of those mentioned above for "compound (C)".
• the ester of a polyoxy C 2 -6 alkylene glycol and a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid may be a commercially available product, or it may be produced by polycondensation of a polyoxy C 2 - 6 alkylene glycol with a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid under known conditions.
• the polyoxy C 2 -6 alkylene glycol to be etherified for the aforementioned ether of a polyoxy C 2 ⁇ e alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol may be any of the polyoxy C 2 - 6 alkylene glycols mentioned above under " (ei) Polyoxy C 2 - 6 alkylene glycol".
• the chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol to be etherified may be, for example, pentaerythritol, glycerin or glycol, mentioned above for "compound (A)".
• C 2 -6 alkylene glycols and chain hydrocarbon tetraols, chain hydrocarbon triols and chain hydrocarbon diols include UNILUBETM 5TP-300KB and UNIOLTM TG-3000 and TG-4000
• UNILUBETM 5TP-300KB is a compound obtained by
• UNIOLTM TG-3000 is a compound obtained by
• UNIOLTM TG-4000 is a compound obtained by
• the ether of a poly C 2 - 6 alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol may also be produced by polycondensation of a polyoxy C 2 - 6 alkylene glycol with a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol under known conditions.
• the chain hydrocarbon has an inorganic value of 0 and thus an IOB of 0.00, while the water solubility is also approximately 0 g, and therefore if the melting point is no higher than about 45°C, it may be included among the aforementioned blood modifying agents.
• chain hydrocarbons examples include (fi) chain alkanes, such as linear alkanes and branched alkanes, and linear alkanes generally include those with no more than 22 carbons, in consideration of a melting point of no higher than about 45°C. In consideration of vapor, pressure, they generally include those with 13 or more carbons. Branched alkanes generally include those with 22 or more carbons, since their melting points are often lower than linear alkanes, given the same number of carbon atoms.
• hydrocarbon products examples include PARLEAM 6 (NOF Corp.).
• the blood modifying agent has been found to have at least a function of lowering blood viscosity and surface tension, which will be considered in detail in the examples. Menstrual blood to be absorbed by the
• absorbent article contains proteins of the endometrial wall, for example, unlike ordinary blood, which binds together blood cells, such that the blood cells form a rouleau state.
• the menstrual blood to be absorbed by the absorbent article therefore tends to have high viscosity, and if the top sheet is a nonwoven fabric of woven fabric, the menstrual blood becomes clogged between the fibers creating a residual sticky feel for the wearer, while the menstrual blood also diffuses on the surface of the top sheet and tends to leak.
• the blood modifying agent has a melting point of no higher than about 45°C, and therefore, whether liquid or solid at ordinary
• the blood modifying agent which has an IOB of about 0.00 to 0.60 has high organicity and readily infiltrates between blood cells, and it therefore
• the blood modifying agent stabilizes blood cells and helps to prevent formation of a rouleau
• an absorbent article comprising an acrylic super- absorbent polymer, or SAP
• absorption of menstrual blood is known to lead to covering of the SAP surface by rouleau-formed blood cells and inhibition of the
• the blood modifying agent which has high affinity with erythrocytes protects the erythrocyte membranes, and therefore may minimize destruction of the erythrocytes .
• Fig. 3 is a plan view showing an absorbent article according to the second embodiment of the invention.
• the absorbent article IB of the second embodiment has in the top sheet 2, an annular inner depressed groove 21B that surrounds a region 26 for facing the excretion hole through which menstrual blood of the wearer is excreted during wearing (in the absorbent article IB of the second embodiment, this is the region at the center in the lengthwise direction and widthwise direction of the absorbent article IB) and that is longer in the
• the inner depressed groove 21B and outer depressed groove 22B are formed by
• the inner depressed groove 21B and outer depressed groove 22B block spread of the menstrual blood in the widthwise direction, and promote efficient migration of the menstrual blood into the absorbent body 4.
• the inner depressed groove 21B and outer depressed groove 22B increase the rigidity of the
• absorbent article IB while reinforcing integration of the top sheet 2, absorbent body 4 and back sheet 3.
• the top sheet 2 also has a blood modifying agent- coated region 8B coated with a blood modifying agent.
• the blood modifying agent-coated region 8B is provided on the top sheet 2 so as to be inside the outer depressed groove 22B, and so that the inner depressed groove 21B is within the blood modifying agent region.
• the blood modifying agent lowers the viscosity and surface tension of menstrual blood and allows rapid migration of menstrual blood from the top sheet 2 to the absorbent body 4, and therefore menstrual blood that has been excreted by the wearer does not easily spread from the blood modifying agent-coated region 8B in the outer planar direction.
• the blood modifying agent-coated region 8B can prevent menstrual blood from reaching the outer depressed groove 22B, and can thus inhibit
• the number of depressed grooves provided in the top sheet 2 is not limited to 2, so long as there is an inner depressed groove 21B and an outer depressed groove 22B surrounding the inner depressed groove 21B.
• Fig. 4 is plan view showing an absorbent article according to a third embodiment of the invention
• Fig. 5 is a schematic cross-sectional view showing a cross-section of the absorbent article of Fig. 4 along line C-C. As shown in Fig. 4 and Fig. 5, a section 61C at the center of the absorbent article 1C in the
• lengthwise direction and/or widthwise direction is higher than the sections on both sides in the lengthwise
• the absorbent article 1C of the third embodiment has a structure wherein the section 61C at the center in the lengthwise direction and/or widthwise direction is higher than the sections on both sides in the lengthwise direction and/or the sections on both sides in the widthwise direction, or in other words, a domed structure.
• the section at the center in the lengthwise direction alone may be higher than in the sections at both sides in the lengthwise direction, or the section at the center in the widthwise direction . alone may be higher than in the sections at both sides in the widthwise direction.
• the domed structure of the absorbent article 1C of the third embodiment can be formed by increasing the basis weight at the center section of the absorbent body above the basis weight at the areas around the center of the absorbent body, by embossing the areas around the center section of the absorbent body, or by providing a cushion sheet at the center section of the absorbent body. This will allow the absorbent article 1C to contact the areas where menstrual blood is excreted by the wearer. In addition, menstrual blood that has been excreted by the wearer will not significantly spread in the planar direction of the top sheet 2, thereby allowing rapid migration of
• the top sheet 2 has a blood modifying agent-coated region 8C, coated with a blood modifying agent, at section 61C where the thickness or height of the
• absorbent article 1C is increased, i.e. at the domed section 61C.
• the blood modifying agent lowers the viscosity and surface tension of
• the domed structure of the absorbent article 1C can further increase the aforementioned effect whereby menstrual blood that has been excreted by the wearer does not significantly spread in the planar direction of the top sheet 2, thus allowing rapid
• the domed structure of the absorbent article 1C that allows the blood modifying agent-coated region 8C of the top sheet 2 to contact the skin of the wearer also increases the skin care effect of the blood modifying agent.
• Fig. 6 is a plan view showing an absorbent article according to the fourth embodiment of the invention.
• a pair of wing sections 7 are each folded inward in the absorbent article ID of the fourth embodiment.
• a release sheet 41 is also attached to the attachment part 12.
• the top sheet 2 of the absorbent article ID has a blood modifying agent-coated region 8D in the region covered by the release sheet 41.
• the release sheet 41 can prevent the blood modifying agent-coated region 8D from being exposed during production of the absorbent article ID, thus preventing the blood modifying agent from attaching to undesired areas during production of the absorbent article ID.
• Fig. 7 is a plan view showing an absorbent article according to the fifth embodiment of the invention.
• a pair of wing sections 7 are each folded inward in the absorbent article IE of the fifth embodiment.
• the top sheet 2 of the absorbent article ID has a blood modifying agent-coated region 8E in the region covered by the pair of wing sections 7 that are folded.
• the part of wing sections 7 can prevent the blood modifying agent- coated region 8E from being exposed during production of the absorbent article IE, thus preventing the blood modifying agent from attaching to undesired areas during production of the absorbent article IE.
• Fig. 8 is a plan view showing an absorbent article according to the sixth embodiment of the invention.
• the length in the lengthwise direction of the region 52 for covering the gluteal region of the wearer is longer than the length in the lengthwise direction of the region 51 for covering the underbelly of the wearer.
• the absorbent article IF of the sixth embodiment is an absorbent article to be worn when the wearer is sleeping, i.e., it is an absorbent . article for night wear.
• the top sheet 2 has a blood modifying agent-coated region 8F, and the blood modifying agent-coated region 8F is provided in the region 26 for facing the excretion hole through which menstrual blood of the wearer is excreted during wearing, and is closer to the region 52 for covering the gluteal region of the wearer than to the region 51 for covering the underbelly of the wearer.
• the blood modifying agent of the blood modifying agent-coated region 8F lowers the viscosity and surface tension even for
• menstrual blood that has flown from the menstrual blood excretion hole of the wearer across the skin to the gluteal region while the wearer is sleeping in a position facing upward, thereby allowing the menstrual blood to rapidly migrate from the top sheet 2 into the absorbent body 4.
• the blood modifying agent lowers the viscosity and surface tension of menstrual blood and allows menstrual blood to rapidly migrate from the top sheet 2 into the absorbent body 4.
• the sanitary napkin was formed from a top sheet, formed of a hydrophilic agent-treated air-through nonwoven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m 2 ), a second sheet, formed of an air-through nonwoven fabric
• an absorbent body comprising pulp (basis weight: 150-450 g/m 2 , increased at the center section)
• an acrylic super-absorbent polymer (basis weight: 15 g/m 2 ) and tissue as a core wrap
• a water-repellent agent-treated side sheet and a back sheet composed of a polyethylene film.
• the blood modifying agents used for the experiment are listed below.
• Glycerin and fatty acid triester with oleic acid or stearylic acid as the fatty acid.
• Tri-C2L oil fatty acid glyceride product of NOF Corp.
• Tri-CL oil fatty acid glyceride product of NOF Corp.
• Glycerin and fatty acid triester with Ci 6 fatty acid:Cis fatty acid:C 2 o fatty acid (including both
• Tri-coconut fatty acid glyceride product of NOF Corp.
• Neopentylglycol di-2-ethylhexanoate weight-average molecular weight: approximately 360.
• Weight-average molecular weight approximately 400
• Weight-average molecular weight approximately 380
• Polypropylene glycol weight-average molecular weight: approximately 1,000
• Polypropylene glycol weight-average molecular weight: approximately 1,160
• Polybutylene glycol weight-average molecular weight: approximately 500
• Polyoxybutylenepolyoxypropylene glycol weight-average molecular weight: approximately 700
• Polybutylene glycol weight-average molecular weight: approximately 1,000
• Polyoxyethylenepolyoxypropylene pentaerythritol ether produced by addition of 5 mol of ethylene oxide and 65 mol of propylene oxide to 1 mol of
• Branched hydrocarbon produced by copolymerization of liquid isoparaffin, isobutene and n-butene followed by hydrogen addition, polymerization degree: approximately 5-10, weight-average molecular weight: approximately 330
• Glycerin and fatty acid monoester with octanoic acid (Cs ) and decanoic acid ( Cio ) at a mass ratio of about 85:15, weight-average molecular weight: approximately 220
• Weight-average molecular weight approximately 230 ⁇ Diisostearyl malate
• Weight-average molecular weight approximately 640
• Polypropylene glycol weight-average molecular weight: approximately 400
• Polyethylene glycol weight-average molecular weight: approximately 1,500-1,600
• Polyoxyethylene monostearate approximately 7 repeating units, weight-average molecular weight:
• Polyoxyethylene hydrogenated castor oil weight-average molecular weight: approximately 3,570
• the IOBs, melting points and water solubilities of the samples are shown in Table 2.
• the skin contact surface of the top sheet of the sanitary napkin was coated with the aforementioned blood modifying agent.
• Each blood modifying agent was used directly, when the blood modifying agent was liquid at room temperature, or when the blood modifying agent was solid at room temperature it was heated to its melting point of +20°C, and a control seam HMA gun was used for atomization of the blood modifying agent and coating onto the entire skin contact surface of the top sheet to a basis weight of about 5 g/m 2 .
• Fig. 9 is . an electron micrograph of the skin contact surface of a top sheet in a sanitary napkin (No.2-5) wherein the top sheet comprises tri-C2L oil fatty acid glycerides. As clearly seen in Fig. 9, the tri-C2L oil fatty acid glycerides are present on the fiber surfaces as fine particulates.
• EDTA ethylenediaminetetraacetic acid
• the acrylic board was immediately removed and 10 sheets of filter paper (Advantec Toyo Kaisha, Ltd, Qualitative Filter Paper No.2, 50 mm x 35 mm) were placed on the location where the blood had been dropped, and then a weight was placed thereover to a pressure of 30 g/cm 2 . After 1 minute, the filter paper was removed and the "rewetting rate" was calculated by the following formula.
• the "absorbent body migration rate" was also measured as the time until migration of blood from the top sheet to the absorbent body after the second dropping of blood.
• the absorbent body migration rate is the time from
• VG Very Good: Virtually no redness of blood remaining, and no clear delineation between areas with and without blood.
• F (Fair) Slight redness of blood remaining, areas with blood discernible.
• the rewetting rate was 22.7% and the absorbent body migration rate was greater than 60 seconds, but the glycerin and fatty acid triesters all produced rewetting rates of no greater than 7.0% and absorbent body migration rates of no longer than 8 seconds, and therefore significantly improved the absorption performance.
• the glycerin and fatty acid triesters no great improvement in absorption performance was seen with NA50 which had a melting point of above 45°C.
• the absorption performance was also significantly improved with blood modifying agents having an IOB of about 0.00-0.60, a melting point of no higher than about 45°C and a water solubility of no greater than about 0.05 g in 100 g of water at 25°C. Rewetting rates of no greater than 7.9% and absorbent body migration rates of no longer than 15 seconds were achieved.
• sanitary napkins Nos. (2-1 )- (2-32 ) and particularly with sanitary napkins that comprised blood modifying agents Nos. (2-1 )- (2-11 ) , (2-15) - (2-19) and (2- 32) , the skin contact surfaces of the top sheets after absorption of menstrual blood had not been reddened by the blood and the unpleasantness was minimal.
• the rewetting rate was evaluated for blood from different animals in accordance with the above
• Defibrinated blood blood sampled and agitated together with glass beads in an Erlenmeyer flask for approximately
• EDTA blood 65 mL of venous blood with addition of 0.5 mL of a 12% EDTA-2K isotonic sodium chloride solution.
• Serum or blood plasma Supernatant obtained after centrifugation of defibrinated blood or EDTA blood for 10 minutes at room temperature at about 1900 G.
• Blood cells Obtained by removing the serum from the blood, washing twice with phosphate buffered saline
• PBS phosphate buffered saline
• An absorbent article was produced in the same manner as Example 2, except that the tri-C2L oil fatty acid glyceride was coated at a basis weight of about 5 g/m 2 , and the rewetting rate of each of the aforementioned blood samples was evaluated. Measurement was performed 3 times for each blood sample, and the average value was recorded.
• the blood retention was evaluated for a top sheet comprising a blood modifying agent and a top sheet comprising no blood modifying agent.
• a tri-C2L oil fatty acid glyceride was atomized on the skin contact surface of a top sheet formed from an air-through nonwoven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m 2 ) , using a control seam HMA gun, for coating to a basis weight of about 5 g/m 2 .
• a sheet without coating with the tri-C2L oil fatty acid glyceride there was also prepared a sheet without coating with the tri-C2L oil fatty acid glyceride.
• both the tri-C2L oil fatty acid glyceride-coated top sheet and the non-coated top sheet were cut to a size of 0.2 g, and the mass (a) of the cell strainer + top sheet was precisely measured.
• the cell strainer was set in a centrifuge tube, and subjected to spin-down to remove the excess horse EDTA blood.
• the measurement was conducted 3 times, and the average value was recorded.
• top sheets comprising blood modifying agents had low blood retentions, suggesting that blood rapidly migrated into the absorbent body after absorption.
• the viscosity of the blood modifying agent- containing blood was measured using a Rheometric
• the mixture was gently agitated to form a sample, the sample was placed on a 50 mm-diameter parallel plate, with a gap of 100 ⁇ , and the viscosity was measured at 37 ⁇ 0.5°C.
• the sample was not subjected to a uniform shear rate due to the parallel plate, but the average shear rate indicated by the device was 10 s -1 .
• the viscosity of the horse defibrinated blood containing 2 mass% PANACET 810s was 5.9 mPa-s, while the viscosity of the horse defibrinated blood containing no blood modifying agent was 50.4 mPa-s.
• the horse defibrinated blood containing 2 mass% PANACET 810s clearly had an approximately 90% lower viscosity than the blood containing no blood modifying agent.
• blood contains components such as blood cells and has thixotropy, and it has been found that the blood modifying agent of this disclosure can lower blood viscosity in the low viscosity range.
• Menstrual blood was sampled from healthy volunteers onto Saran wrap, and PANACET 810s dispersed in a 10-fold mass of phosphate-buffered saline was added to a portion thereof to a PANACET 810s concentration of 1 mass%.
• the menstrual blood was dropped onto a slide glass, a cover glass was placed thereover, and the state of the
• erythrocytes was observed with an optical microscope.
• a photomicrograph of menstrual blood containing no blood modifying agent is shown in Fig. 10(a), and a
• erythrocytes formed aggregates such as rouleaux in the menstrual blood containing no blood modifying agent, while the
• erythrocytes were stably dispersed in the menstrual blood containing PANACET 810s. This suggests that the blood modifying agent functions to stabilize erythrocytes in blood.
• the surface tension of blood containing a blood modifying agent was measured by the pendant drop method, using a Drop Master500 contact angle meter by Kyowa
• the surface tension was measured after adding a prescribed amount of blood modifying agent to sheep defibrinated blood, and
• the measurement was accomplished automatically with a device, and the surface tension ⁇ was determined by the following formula (see Fig. 11) .
• the density p was measured at the temperatures listed in Table 5, according to JIS K 2249-1995, "Densit test methods and density/mass/volume conversion tables", "5. Vibrating density test method”.
• the measurement was accomplished using a DA-505 by Kyoto Electronics Co., Ltd.
• Table 5 shows that the blood modifying agent can lower the surface tension of blood despite its very low solubility in water, as seen by a water solubility of about 0.00-about 0.05 g in 100 g of water at 25°C.
• An absorbent article having a lengthwise direction and a widthwise direction, and comprising a liquid- permeable top sheet provided on the skin facing side, a liquid-impermeable back sheet provided on the non-skin facing side, and a liquid-retaining absorbent body situated between the top sheet and the back sheet,
• the top sheet has a blood modifying agent-coated region on which a blood modifying agent is coated
• the blood modifying agent has an IOB of 0.00- 0.60, a melting point of no higher than 45°C and a water solubility of no greater than 0.05 g in 100 g of water at 25°C, and
• the blood modifying agent-coated region does not reach to the edges of the absorbent article.
• An absorbent article according to Jl wherein the vapor pressure of the blood modifying agent is about 0.00-0.01 Pa, preferably about 0.000-0.001 Pa and more preferably about 0.0000-0.0001 Pa, at 1 atmosphere, 25°C, or at 1 atmosphere, 40°C.
• top sheet has an absorbent body region at which the absorbent body is present on the non-skin facing side of the top sheet
• the blood modifying agent-coated region is within the absorbent body region.
• An absorbent article which further comprises a pair of side sheets provided on both sides of the top sheet in the widthwise direction,
• the blood modifying agent-coated region does not reach to the region where the top sheet and side sheet overlap.
• top sheet has an annular inner depressed groove that surrounds the region facing the excretion hole through which menstrual blood is excreted by the wearer during wearing, and which is longer in the lengthwise direction than the widthwise direction, and an outer depressed groove surrounding the inner depressed groove, and
• the blood modifying agent-coated region is provided on the top sheet on the inside of the outer depressed groove, in such a manner that the inner
• depressed groove is included within the blood modifying agent region.
• An absorbent article which has a domed section in which the bulk at the center in the lengthwise direction and/or widthwise direction is greater than at the sections on both sides in the lengthwise direction and/or at the sections on both sides in the widthwise direction of the absorbent article,
• top sheet has the blood modifying agent-coated region in the domed section.
• the pair of wing sections each being folded inward in the widthwise direction on the skin facing side
• the top sheet having the blood modifying agent- coated region within the region covered by the release sheet.
• the pair of wing sections each being folded inward in the widthwise direction on the skin facing side
• the top sheet having the blood modifying agent- coated region within the regions covered by the pair of wing sections that are folded.
• An absorbent article which comprises a region covering the gluteal region of the wearer and a region covering the underbelly of the wearer,
• the blood modifying agent-coated region is provided in the region facing the excretion hole through which menstrual blood of the wearer is excreted during wearing, closer to the region covering the gluteal region of the wearer.
• hydrocarbon moiety and (iii-3) one or more groups each selected from the group consisting of carboxyl group (- COOH) and hydroxyl group (-OH) substituting a hydrogen of the hydrocarbon moiety;
• (ii 1 ) a compound having (ii'-l) a hydrocarbon moiety, and (ii'-2) one or more bonds each selected from the group consisting of carbonyl bond (-CO-), ester bond
• (iii 1 ) a compound having (iii'-l) a hydrocarbon moiety, (iii '-2) one or more bonds each selected from the group consisting of carbonyl bond (-CO-) , ester bond (- COO-) , carbonate bond (-OCOO-) , and ether bond (-0-) inserted between a C-C single bond of the hydrocarbon moiety, and (iii '-3) one or more groups each selected from the group consisting of carboxyl group (-COOH) and hydroxyl group (-OH) substituting a hydrogen on the hydrocarbon moiety;
• the blood modifying agent is selected from the group consisting of following items (A) -(F), and any combination thereof:
• the blood modifying agent is selected from the group consisting of (ai) esters of chain hydrocarbon tetraols and fatty acids, (a 2 ) esters of chain hydrocarbon triols and fatty acids, (a3) esters of chain hydrocarbon diols and fatty acids, (b ⁇ ) ethers of chain hydrocarbon tetraols and aliphatic monohydric alcohols, (b 2 ) ethers of chain hydrocarbon triols and aliphatic monohydric
• esters of chain hydrocarbon diols and aliphatic monohydric alcohols (b3) ethers of chain hydrocarbon diols and aliphatic monohydric alcohols, (ci) esters of chain hydrocarbon tetracarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 4 carboxyl groups, and aliphatic monohydric alcohols, (c 2 ) esters of chain hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 3 carboxyl groups, and aliphatic monohydric alcohols, (03) esters of chain hydrocarbon dicarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 2 carboxyl groups, and aliphatic monohydric alcohols, (di) ethers of aliphatic monohydric alcohols and aliphatic monohydric alcohols, (d 2 ) dialkyl ketones, (d 3 ) esters of fatty acids and ali
• the blood modifying agent is selected from the group consisting of (ai) esters of chain hydrocarbon tetraols and fatty acids, (a 2 ) esters of chain hydrocarbon triols and fatty acids, (a3) esters of chain hydrocarbon diols and fatty acids, (c 2 ) esters of chain hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 3 carboxyl groups, and aliphatic monohydric alcohols, (C3) esters of chain hydrocarbon dicarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 2 carboxyl groups, and aliphatic monohydric alcohols, (d3.) esters of fatty acids and aliphatic monohydric alcohols, (ei) polyoxy C 2 -6 alkylene glycols, (e 2 ) esters of polyoxy C 2 -6 alkylene glycols and at least one fatty acid, (e3) ethers of polyoxy

Landscapes

• Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Vascular Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Fluid Mechanics (AREA)
• Physics & Mathematics (AREA)
• Absorbent Articles And Supports Therefor (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47995890

Family Applications (1)

Country Status (4)

Cited By (3)

Families Citing this family (3)

Citations (3)

Family Cites Families (11)

• 2011
  • 2011-09-30 JP JP2011217854A patent/JP5916327B2/ja active Active
• 2012
  • 2012-09-25 AR ARP120103534 patent/AR088016A1/es active IP Right Grant
  • 2012-09-25 WO PCT/JP2012/075290 patent/WO2013047867A1/en active Application Filing
  • 2012-09-27 TW TW101135564A patent/TWI619477B/zh active

Patent Citations (3)

Also Published As

Similar Documents

Legal Events